Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Update to Johnson & Johnson PFA platform gains FDA approval
The Varipulse PFA platform originally gained FDA approval in 2024. According to Johnson & Johnson MedTech, this update was put in place to help the technology provide better patient outcomes going forward.
AI-enhanced echocardiography improves early detection of cardiac amyloidosis
The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.
AI-enabled coronary plaque evaluations included in new RBM guidelines
The use of advanced AI software to assess CCTA images continues to gain more momentum.
ASE shares new recommendations for evaluating LV diastolic function, HFpEF
The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions.
Cardiology still No. 2 in FDA-cleared clinical AI algorithms, trailing only radiology
Cardiology continues to be one of the most influential healthcare specialties when it comes to utilizing artificial intelligence.

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

Update to Johnson & Johnson PFA platform gains FDA approval

The Varipulse PFA platform originally gained FDA approval in 2024. According to Johnson & Johnson MedTech, this update was put in place to help the technology provide better patient outcomes going forward.

Ultromics EchoGo Amyloidosis artificial intelligence

AI-enhanced echocardiography improves early detection of cardiac amyloidosis

The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.

AI-enabled coronary plaque evaluations included in new RBM guidelines

The use of advanced AI software to assess CCTA images continues to gain more momentum.

ASE shares new recommendations for evaluating LV diastolic function, HFpEF

The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions.

An example of artificial intelligence automated coronary artery calcium scoring shown by Coreline at ACC23. The AI also identifies and color codes the anatomy so help show the reviewing radiologist or cardiac imager what and where things were calculated. #ACC #ACC23

Cardiology still No. 2 in FDA-cleared clinical AI algorithms, trailing only radiology

Cardiology continues to be one of the most influential healthcare specialties when it comes to utilizing artificial intelligence.

Congress Money washington DC legislation coverage payment

With MPFS proposal on the way, electrophysiology groups outline their priorities

The Heart Rhythm Society and its new advocacy arm plan on pushing CMS to include certain policy improvements in the 2026 MPFS.

AI completes CAC assessment using routine LDCT scan

AI enables tracking of coronary artery calcium growth on routine lung cancer CT scans

New data suggest increases in CAC scores between lung cancer screenings strongly correlates with the risk of adverse cardiovascular events.

Farapulse Boston Scientific Pulsed Field Ablation PFA fda approval

FDA expands approval of Boston Scientific’s Farapulse PFA system

The FDA's 2024 approval of the Farapulse system covered patients with paroxysmal atrial fibrillation. Now, however, the technology is officially approved for patients with more persistent symptoms.